





Medicina ed Intelligenza Artificiale

Esperienze e considerazioni

Robert Alexander – 4 Maggio 2021

bob@ralexander.it

AI sciences applied as technology



Sensing

Knowledge

Statistics

Bias
removal

Memory



Colerick.



The Colerick p-
son yb hote, drye,
lene, slend^r, conc
tonb, yresfull, ha
siv, dereitfull, &

Sanguine.



The Sanguine
pson yb hote, mo
ist, liberall, plen
teonb, mery, an
ddy, he drawith

Flegmatick.



The flegmatick
pson is cold, and
moist, heavy, stom
slepy, ingenioune
he spitteth, when

Melancoly.




The melancoly
pson is cold, drye,
heavy, conc tonb,
barbit^r, malicionb,
& stowe, he lowith

Part 1 Metabolic Pathways


Roche Biochemical Pathways
4th Edition, Part 1 - Editor: Gerhard Michal

Roche

CONTENTS	1
1. METABOLISM	1
2. ENERGY METABOLISM	1
3. CARBOHYDRATE METABOLISM	1
4. LIPID METABOLISM	1
5. NUCLEIC ACID METABOLISM	1
6. AMINO ACID METABOLISM	1
7. BIOSYNTHESIS	1
8. DETOXIFICATION	1
9. SIGNAL TRANSDUCTION	1
10. CELLULAR HOMEOSTASIS	1
11. CELL DEATH	1
12. CELLULAR COMMUNICATION	1
13. CELLULAR MOTILITY	1
14. CELLULAR DIFFERENTIATION	1
15. CELLULAR REPRODUCTION	1
16. CELLULAR DEVELOPMENT	1
17. CELLULAR AGING	1
18. CELLULAR DISEASE	1
19. CELLULAR THERAPY	1
20. CELLULAR TOXICOLOGY	1
21. CELLULAR PHARMACOLOGY	1
22. CELLULAR BIOCHEMISTRY	1
23. CELLULAR PHYSIOLOGY	1
24. CELLULAR PATHOLOGY	1
25. CELLULAR GENETICS	1
26. CELLULAR MOLECULAR BIOLOGY	1
27. CELLULAR CELL BIOLOGY	1
28. CELLULAR CELL PHYSIOLOGY	1
29. CELLULAR CELL PATHOLOGY	1
30. CELLULAR CELL GENETICS	1
31. CELLULAR CELL MOLECULAR BIOLOGY	1
32. CELLULAR CELL CELL BIOLOGY	1
33. CELLULAR CELL CELL PHYSIOLOGY	1
34. CELLULAR CELL CELL PATHOLOGY	1
35. CELLULAR CELL CELL GENETICS	1
36. CELLULAR CELL CELL MOLECULAR BIOLOGY	1
37. CELLULAR CELL CELL CELL BIOLOGY	1
38. CELLULAR CELL CELL CELL PHYSIOLOGY	1
39. CELLULAR CELL CELL CELL PATHOLOGY	1
40. CELLULAR CELL CELL CELL GENETICS	1
41. CELLULAR CELL CELL CELL MOLECULAR BIOLOGY	1
42. CELLULAR CELL CELL CELL CELL BIOLOGY	1
43. CELLULAR CELL CELL CELL CELL PHYSIOLOGY	1
44. CELLULAR CELL CELL CELL CELL PATHOLOGY	1
45. CELLULAR CELL CELL CELL CELL GENETICS	1
46. CELLULAR CELL CELL CELL CELL MOLECULAR BIOLOGY	1
47. CELLULAR CELL CELL CELL CELL CELL BIOLOGY	1
48. CELLULAR CELL CELL CELL CELL CELL PHYSIOLOGY	1
49. CELLULAR CELL CELL CELL CELL CELL PATHOLOGY	1
50. CELLULAR CELL CELL CELL CELL CELL GENETICS	1
51. CELLULAR CELL CELL CELL CELL CELL MOLECULAR BIOLOGY	1
52. CELLULAR CELL CELL CELL CELL CELL CELL BIOLOGY	1
53. CELLULAR CELL CELL CELL CELL CELL CELL PHYSIOLOGY	1
54. CELLULAR CELL CELL CELL CELL CELL CELL PATHOLOGY	1
55. CELLULAR CELL CELL CELL CELL CELL CELL GENETICS	1
56. CELLULAR CELL CELL CELL CELL CELL CELL MOLECULAR BIOLOGY	1
57. CELLULAR CELL CELL CELL CELL CELL CELL CELL BIOLOGY	1
58. CELLULAR CELL CELL CELL CELL CELL CELL CELL PHYSIOLOGY	1
59. CELLULAR CELL CELL CELL CELL CELL CELL CELL PATHOLOGY	1
60. CELLULAR CELL CELL CELL CELL CELL CELL CELL GENETICS	1
61. CELLULAR CELL CELL CELL CELL CELL CELL CELL MOLECULAR BIOLOGY	1
62. CELLULAR CELL CELL CELL CELL CELL CELL CELL CELL BIOLOGY	1
63. CELLULAR CELL CELL CELL CELL CELL CELL CELL CELL PHYSIOLOGY	1
64. CELLULAR CELL CELL CELL CELL CELL CELL CELL CELL PATHOLOGY	1
65. CELLULAR CELL CELL CELL CELL CELL CELL CELL CELL GENETICS	1
66. CELLULAR CELL CELL CELL CELL CELL CELL CELL CELL MOLECULAR BIOLOGY	1
67. CELLULAR CELL CELL CELL CELL CELL CELL CELL CELL CELL BIOLOGY	1
68. CELLULAR CELL CELL CELL CELL CELL CELL CELL CELL CELL PHYSIOLOGY	1
69. CELLULAR CELL CELL CELL CELL CELL CELL CELL CELL CELL PATHOLOGY	1
70. CELLULAR CELL CELL CELL CELL CELL CELL CELL CELL CELL GENETICS	1
71. CELLULAR CELL CELL CELL CELL CELL CELL CELL CELL CELL MOLECULAR BIOLOGY	1
72. CELLULAR CELL CELL CELL CELL CELL CELL CELL CELL CELL CELL BIOLOGY	1
73. CELLULAR CELL CELL CELL CELL CELL CELL CELL CELL CELL CELL PHYSIOLOGY	1
74. CELLULAR CELL CELL CELL CELL CELL CELL CELL CELL CELL CELL PATHOLOGY	1
75. CELLULAR CELL CELL CELL CELL CELL CELL CELL CELL CELL CELL GENETICS	1
76. CELLULAR CELL CELL CELL CELL CELL CELL CELL CELL CELL CELL MOLECULAR BIOLOGY	1
77. CELLULAR CELL CELL CELL CELL CELL CELL CELL CELL CELL CELL CELL BIOLOGY	1
78. CELLULAR CELL CELL CELL CELL CELL CELL CELL CELL CELL CELL CELL PHYSIOLOGY	1
79. CELLULAR CELL CELL CELL CELL CELL CELL CELL CELL CELL CELL CELL PATHOLOGY	1
80. CELLULAR CELL CELL CELL CELL CELL CELL CELL CELL CELL CELL CELL GENETICS	1
81. CELLULAR CELL CELL CELL CELL CELL CELL CELL CELL CELL CELL CELL MOLECULAR BIOLOGY	1
82. CELLULAR CELL CELL CELL CELL CELL CELL CELL CELL CELL CELL CELL CELL BIOLOGY	1
83. CELLULAR CELL CELL CELL CELL CELL CELL CELL CELL CELL CELL CELL CELL PHYSIOLOGY	1
84. CELLULAR CELL CELL CELL CELL CELL CELL CELL CELL CELL CELL CELL CELL PATHOLOGY	1
85. CELLULAR CELL CELL CELL CELL CELL CELL CELL CELL CELL CELL CELL CELL GENETICS	1
86. CELLULAR CELL CELL CELL CELL CELL CELL CELL CELL CELL CELL CELL CELL MOLECULAR BIOLOGY	1
87. CELLULAR CELL CELL CELL CELL CELL CELL CELL CELL CELL CELL CELL CELL CELL BIOLOGY	1
88. CELLULAR CELL CELL CELL CELL CELL CELL CELL CELL CELL CELL CELL CELL CELL PHYSIOLOGY	1
89. CELLULAR CELL CELL CELL CELL CELL CELL CELL CELL CELL CELL CELL CELL CELL PATHOLOGY	1
90. CELLULAR CELL CELL CELL CELL CELL CELL CELL CELL CELL CELL CELL CELL CELL GENETICS	1
91. CELLULAR CELL CELL CELL CELL CELL CELL CELL CELL CELL CELL CELL CELL CELL MOLECULAR BIOLOGY	1
92. CELLULAR CELL CELL CELL CELL CELL CELL CELL CELL CELL CELL CELL CELL CELL CELL BIOLOGY	1
93. CELLULAR CELL CELL CELL CELL CELL CELL CELL CELL CELL CELL CELL CELL CELL CELL PHYSIOLOGY	1
94. CELLULAR CELL CELL CELL CELL CELL CELL CELL CELL CELL CELL CELL CELL CELL CELL PATHOLOGY	1
95. CELLULAR CELL CELL CELL CELL CELL CELL CELL CELL CELL CELL CELL CELL CELL CELL GENETICS	1
96. CELLULAR CELL CELL CELL CELL CELL CELL CELL CELL CELL CELL CELL CELL CELL CELL MOLECULAR BIOLOGY	1
97. CELLULAR CELL CELL CELL CELL CELL CELL CELL CELL CELL CELL CELL CELL CELL CELL CELL BIOLOGY	1
98. CELLULAR CELL CELL CELL CELL CELL CELL CELL CELL CELL CELL CELL CELL CELL CELL CELL PHYSIOLOGY	1
99. CELLULAR CELL CELL CELL CELL CELL CELL CELL CELL CELL CELL CELL CELL CELL CELL CELL PATHOLOGY	1
100. CELLULAR CELL CELL CELL CELL CELL CELL CELL CELL CELL CELL CELL CELL CELL CELL CELL GENETICS	1




Humans are defined by a multilevel complex system: to socio-ecology




Health -> Systems science

Medical cognition model: experience vs analysis

Dual processing theory in action




CAUSE



Factors impacting clinical outcomes

Knowledge Cognition

(Expertise, self-regulation, deliberate practice, instructional format, sleepiness, well-being)




(Acuity of illness, spoken English proficiency, emotional volatility, support structures)

Organization

(Appointment length, ambulatory or inpatient setting, common versus rare presentation, staffing)

Resources

Gartner Hype Cycle for Artificial Intelligence, 2019



gartner.com/SmarterWithGartner

Source: Gartner
 © 2019 Gartner, Inc. and/or its affiliates. All rights reserved.

Gartner

Computer Science > Machine Learning

[Submitted on 6 Nov 2020 (v1), last revised 24 Nov 2020 (this version, v2)]

Underspecification Presents Challenges for Credibility in Modern Machine Learning

Alexander D'Amour, Katherine Heller, Dan Moldovan, Ben Adlam, Babak Alipanahi, Alex Beutel, Christina Chen, Jonathan Deaton, Jacob Eisenstein, Matthew D. Hoffman, Farhad Hormozdiari, Neil Houlsby, Shaobo Hou, Ghassen Jerfel, Alan Karthikesalingam, Mario Lucic, Yian Ma, Cory McLean, Diana Mincu, Akinori Mitani, Andrea Montanari, Zachary Nado, Vivek Natarajan, Christopher Nielson, Thomas F. Osborne, Rajiv Raman, Kim Ramasamy, Rory Sayres, Jessica Schrouff, Martin Seneviratne, Shannon Sequeira, Harini Suresh, Victor Veitch, Max Vladymyrov, Xuezhi Wang, Kellie Webster, Steve Yadlowsky, Taedong Yun, Xiaohua Zhai, D. Sculley

ML models often exhibit unexpectedly poor behavior when they are deployed in real-world domains. We identify underspecification as a key reason for these failures. An ML pipeline is underspecified when it can return many predictors with equivalently strong held-out performance in the training domain. Underspecification is common in modern ML pipelines, such as those based on deep learning. Predictors returned by underspecified pipelines are often treated as equivalent based on their training domain performance, but we show here that such predictors can behave very differently in deployment domains. This ambiguity can lead to instability and poor model behavior in practice, and is a distinct failure mode from previously identified issues arising from structural mismatch between training and deployment domains. We show that this problem appears in a wide variety of practical ML pipelines, using examples from computer vision, medical imaging, natural language processing, clinical risk prediction based on electronic health records, and medical genomics. Our results show the need to explicitly account for underspecification in modeling pipelines that are intended for real-world deployment in any domain.



Original image



Dermatoscopic image of a benign melanocytic nevus, along with the diagnostic probability computed by a deep neural network.



Diagnosis: Benign

The patient has a history of **back pain** and chronic **alcohol abuse** and more recently has been seen in several...


Opioid abuse risk: High

277.7 Metabolic syndrome
429.9 Heart disease, unspecified
278.00 Obesity, unspecified

Reimbursement: Denied

+ 0.04 ×

Adversarial noise




Perturbation computed by a common adversarial attack technique. See (7) for details.

=

Adversarial example



Combined image of nevus and attack perturbation and the diagnostic probabilities from the same deep neural network.



Diagnosis: Malignant


The patient has a history of **lumbago** and chronic **alcohol dependence** and more recently has been seen in several...

Opioid abuse risk: Low

401.0 Benign essential hypertension
272.0 Hypercholesterolemia
272.2 Hyperglyceridemia
429.9 Heart disease, unspecified
278.00 Obesity, unspecified


Reimbursement: Approved

Adversarial rotation (8)




Adversarial text substitution (9)

Adversarial coding (13)



NEURAL NETWORKS


+



```
(:action pickup
:parameters (?b1 ?b2 - block)
:precondition (and (on ?b1 ?b2)
                   (hand-clear))
:effect (and (not (hand-clear))
             (not (on ?b1 ?b2))
             (holding ?b1))
)
```


SYMBOLIC AI

Neurosymbolic Generative Models




Srivastava et al. 2020 (submitted)

Neurosymbolic Safe ML/RL




Fulton et al AAAI 2018

Neurosymbolic NLU




Wilcox et al. NAACL 2019

Neurosymbolic Planning




Asai et al. AAAI 2018

Neurosymbolic Code Optimization



Shi et al. ICLR 2019

Neurosymbolic Machine Common Sense




Smith et al. NeurIPS 2019

Coronavirus Covid-19: Campus Biomedico Roma, acquisito sistema di intelligenza artificiale per diagnosi precoce utilizzato a Wuhan

18 marzo 2020 @ 18:44



“Il sistema di intelligenza artificiale – si legge in una nota – è in grado di fornire una risposta in 20 secondi partendo dall’analisi delle immagini della Tc polmonare”. “Il tasso di attendibilità – viene spiegato – è del 98,5% ed è stato testat THE LANCET Digital Health pazienti anonimizzati in cieco dai medici radiologi del Policlin



Cautions about radiologic diagnosis of COVID-19 infection driven by artificial intelligence

Andrea Laghi

Open Access • Published: May, 2020 • DOI: [https://doi.org/10.1016/S2589-7500\(20\)30079-0](https://doi.org/10.1016/S2589-7500(20)30079-0)

References

Article Info

Linked Articles

I read with interest the piece by Becky McCall¹ in *The Lancet Digital Health*. The author interviews several experts from different health-care sectors about the possible role of artificial intelligence (AI) in tackling coronavirus disease 2019 (COVID-19).


On the one hand, I agree that because AI is causing a paradigm shift in health care there could be many possible uses of AI during this COVID-19 outbreak.¹

• View related content for this article

On the other hand, as a radiologist, I disagree with some of the optimistic expectations about the diagnostic value of a particular algorithm applied to lung CT images as outlined by McCall because, in my opinion, this is not yet supported by scientific evidence.

Unfortunately, the little evidence that has been reported shows that approximately 50% of patients with COVID-19 infection have a normal CT scan, if scanned early after the onset of symptoms.² This evidence is the main reason why the American College of Radiology does not consider CT imaging as a useful screening test in asymptomatic individuals.³

One of the experts that McCall interviewed states that “while a manual read of a CT scan can take up to 15 minutes, AI can finish reading the image in 10 seconds”. I don’t think this is in line with the daily diagnostic reality. To detect a diffuse lung parenchyma abnormality, a non-specialised radiologist takes a few seconds to scroll the entire image dataset and there is also no risk of not identifying the lesion because it is extremely obvious.



Abstract

Objectives To discuss the evidence supporting the use of artificial intelligence (AI) in the diagnosis of COVID-19.

Background The use of AI in the diagnosis of COVID-19 is a topic of growing interest. However, the evidence supporting its use is limited.

Methods We conducted a systematic review of the literature to identify studies that evaluated the use of AI in the diagnosis of COVID-19.

Results We identified 10 studies that evaluated the use of AI in the diagnosis of COVID-19. The studies included 1,000 patients.

Conclusions The use of AI in the diagnosis of COVID-19 is a topic of growing interest. However, the evidence supporting its use is limited.

Keywords Artificial intelligence, COVID-19, diagnosis, radiology.

Introduction The use of artificial intelligence (AI) in the diagnosis of COVID-19 is a topic of growing interest. However, the evidence supporting its use is limited.

Background The use of AI in the diagnosis of COVID-19 is a topic of growing interest. However, the evidence supporting its use is limited.

Methods We conducted a systematic review of the literature to identify studies that evaluated the use of AI in the diagnosis of COVID-19.

Results We identified 10 studies that evaluated the use of AI in the diagnosis of COVID-19. The studies included 1,000 patients.

Conclusions The use of AI in the diagnosis of COVID-19 is a topic of growing interest. However, the evidence supporting its use is limited.

Keywords Artificial intelligence, COVID-19, diagnosis, radiology.

Introduction The use of artificial intelligence (AI) in the diagnosis of COVID-19 is a topic of growing interest. However, the evidence supporting its use is limited.

Background The use of AI in the diagnosis of COVID-19 is a topic of growing interest. However, the evidence supporting its use is limited.

Methods We conducted a systematic review of the literature to identify studies that evaluated the use of AI in the diagnosis of COVID-19.


Results We identified 10 studies that evaluated the use of AI in the diagnosis of COVID-19. The studies included 1,000 patients.

Conclusions The use of AI in the diagnosis of COVID-19 is a topic of growing interest. However, the evidence supporting its use is limited.

Keywords Artificial intelligence, COVID-19, diagnosis, radiology.

Introduction The use of artificial intelligence (AI) in the diagnosis of COVID-19 is a topic of growing interest. However, the evidence supporting its use is limited.

Cambi d'aria per ora	Minuti richiesti per la rimozione contaminanti	
	99%	99,9%
1	276	414
6	46	69
10	28	41
15	18	28
20	14	21
50	6	8




a The number of studies as found on Pubmed.com using the search term “machine learning” OR “deep learning”) and choosing a year in advanced search. **b** The same search method was used followed by (AND specialty) without specifying a time frame. The number in the circles determine how many studies we found.

[Back to article page >](#)

Distribution of the number of encounters for the selected cohort to go from “Aortic valve disorder (disorder)” to “Aortic stenosis, non-rheumatic (disorder)”



In the majority of the patients both features are found during the same hospital encounter, however for some patients the journey is longer and takes up to 12 encounters considering a maximum temporal window of 60days.




All the pathways of all the patients are computed and aggregated to show the cohort Sankey diagram

The next 3 slides show the pathways of selected patients at a glance with 1, 3, and 12 encounters



1 patient from the base query with temporal evolution along a maximum of 60 days
The patient with least encounters: the same day both start and end events happened



1 patient from the base query with temporal evolution along a maximum of 60 days
 A patient with 3 encounters over 11 days



1 patient from the base query with temporal evolution along a maximum of 60 days
 The patient with most encounters in the cohort with maximum time window of 60 days



Uomo 89 anni

-ipertensione arteriosa labile;
- '94 episodio di diplopia (indagato con TAC e Doppler dei vasi epiaortici); da allora seguito dal dott. Alberti per riscontro di soffio da insufficienza aortica non severa;
- '95 ECO: dilatazione ed ipertrofia ventricolare sinistra; insufficienza aortica di media severità, normale funzione ventricolare sinistra;
- '96 segnalata disfunzione Vsin; indagine emodinamica: FEVS ai limiti (58%), coronarie normali, IAO grado 2. fibrillazione atriale parossistica durante la degenza.
- '99 sincope verosimilmente vasovagale. ECO e HOLTER negativi.
- successivi controlli c/o il CCV;
-2005 visita cardiologica per episodi di dispnea da sforzo ed edemi arti inferiori: riscontro ECG ed Holter di bradicardia sinusale, BAV I grado, BAV II M1 ed M2, BAV avanzato con episodi di dissociazione AV; all'ECO: Vsin con ipocinesia infero settale ed inferiore con FE conservata, Vdx normocinetico. Moderata dilatazione atriale sinistra e lieve destra. Stenosi aortica lieve ed insufficienza aortica moderata.
Trattato con impianto di PM DDD 4 /2005.

-3-2008 ricovero in medicina d'urgenza e dimesso con diagnosi di IMA Broncopolmonite destra, disfunzione Vsn severa, Ipertensione arteriosa. BBsn completo. malattia da reflusso gastroesofageo. Morbo di Parkinson.
-successivo controllo presso la Pineta del carso per edemi importanti e episodi di oppressione toracica.
5-2008 visita cardiologica per persistenza di edemi declivi ed episodi di oppressione toracica: Dorme con un cuscino alto, non riferisce dispnea parossistica notturna. non dispnea da sforzo. Episodi di oppressione toracica a destra forse atipici.

EO: Dolore (0-10): 0 Moderati edmi declivi, polsi distali sembrano pesanti, Addome trattabile. Attività cardica ritmica, 3° tono, soffio da IM, IT e soffio aortico sistolico. Non soffi carotidei. PA 155/70 mmHg.
5-2008 ECG RS 68 /min. occasionali extrasistoli ventricolari. BBsn completo. Modificata la terapia con introduzione di digitale

-06/06/2008 ECG Ritmo sinusale 61/min, Blocco di branca sinistra completo

-13/06/2008 AGGIORNAMENTO

In considerazione alla modificazioni della terapia con aggiunta della digitale l'ECG mostra buone frequenze senza evidenza di ritardi di conduzione.

Continui con la terapia in atto.

-22-1-09 visita CCV: asintomatico/paucisintomatico per dispnea (NYHA I-II), sporadici episodi notturni a riposo di fastidio all'emitorace dx di tipo oppressivo a risoluzione spontanea in minuti, PA 140/62, problemi di deambulazione per m di Parkinson

EO: peso 70,100Kg (stabile)x175cm, PV =0, RAG assente, Attività cardiaca ritmica, soffio da IM 1-2/6 e soffio aortico sistolico 2/6 e protodiastolico PS3. Non soffi carotidei. PA 140/60 mmHg, edemi malleolari ++

E.C.G. : ritmo indotto da pacemaker (atrioguidato) 60 bpm deviazione assiale sinistra blocco di branca sinistra

-1-10-09 visita CCV: asintomatico, PA ben controllata

EO: PV =0, RAG assente, Attività cardiaca ritmica, soffio da IM 1-2/6 e soffio aortico sistolico 2/6 e protodiastolico PS3, edemi malleolari ++

Altezza: 170 cm Peso: 69,5 Kg FC: 60 B/min PA: 140 / 80mmHg BSA: 1,8 BMI: 24,05 E.C.G. : ritmo indotto da pacemaker con stimolazione atriale, fc 60 bpm, ben funzionante

-13-4-10 visita CCV: asintomatico

EO PV =0, RAG assente, Attività cardiaca ritmica, soffio da IM 1-2/6 e soffio aortico sistolico 2/6 e protodiastolico PS3, edemi malleolari ++

Altezza: 172 cm Peso: 70,0 Kg FC: 65 B/min

PA: 140 / 55 mmHg BSA: 1,83

E.C.G. ritmo sinusale e talora indotto da pacemaker, occasionali extrasistoli ventricolari con occasionali extrasistoli sopraventricolari

blocco di branca sinistra completo

-30-12-10 visita CCV pauci/asintomatico dal punto di vista cardiologico, deambula con difficoltà per Parkinson invalidante, viene in visita in carrozzina accompagnato dal nipote

Esame obiettivo

Esame Obiettivo: PV =0, RAG assente, Attività cardiaca ritmica, soffio da IM 1-2/6 e soffio aortico sistolico 2/6 e protodiastolico PS3, edemi malleolari ++

Parametri funzionali

Altezza: 170 cm FC: 60 B/min

PA: 120 / 80 mmHg

Esami Strumentali:

E.C.G. 30-12-2010

Referto: ritmo indotto da pacemaker bicamerale 60bpm

Diagnosi

Cardiopatia ipertensiva e valvolare

Cardiopatia ischemica con severa disfunzione ventricolare sinistra

Ipertensione Arteriosa controllata in terapia

Insufficienza della Valvola Aortica di grado moderato

Blocco Atrioventricolare avanzato con dissociazione AV.

Blocco di Branca Sinistra completo

Fibrillazione atriale parossistico/a

Scompenso Cardiaco Cronico congestizio controllato in terapia

Dislipidemia mista di grado lieve

Aneurisma vascolare dell'aorta ascendente (radice aortica 4.1cm)

Prescrizione

LASIX 25 MG 1-2 cp die da adeguare secondo peso, diuresi ed edemi declivi.

MESALAZINA "400 MG COMPRESSE GASTRORESISTENTI" 50 COMPRESSE

GASTRORESISTENTI 1 cp ore 8.

CARDIOASPIRIN 100 MG 1 cp ore 13 (a stomaco pieno).

LANSOPRAZOLO DOC - 30MG 14CPS 30MG 14CPS 1 cp ore 8.

MONOKET "MULTITAB" 60 MG 1 cp ore 8.

STALEVO - 100+25+200MG 100CPR 100+25+200MG 100CPR 1 cp x 5 di

ENALAPRIL ACV - 5MG 28CPR 5MG 28CPR 1 cp x 2 (ore 8-20)

Raccomandazioni al paziente (inutile)

Si raccomanda la profilassi dell'endocardite infettiva

La profilassi antibiotica dell'endocardite batterica e' altamente raccomandata in pazienti con protesi valvolari cardiache, pregressa endocardite batterica, cardiopatie congenite e valvulopatie prima di eseguire procedure dentarie (estrazioni, procedure periodontali, implantologia, pulizia dentale e rimozione del tartaro e comunque tutte le procedure in cui si puo' verificare sanguinamento), procedure chirurgiche del tratto respiratorio (inclusa broncoscopia con broncoscopio rigido), del tratto gastrointestinale (incluse le procedure endoscopiche se associate a prelievo biptico) e urinario (inclusa cistoscopia).

Non necessitano generalmente di profilassi antibiotica procedure di intubazione endotracheale, broncoscopia con broncoscopio flessibile, ecocardiogramma transesofageo, esofagogastroduodenoscopia (senza prelievo biptico), cateterismo cardiaco, compresa angioplastica. Un'alimentazione corretta ed equilibrata e' molto importante. Al posto di cibi troppo grassi, preferite alimenti che contengono fibre e carboidrati (pane, pasta, cereali, riso, patate). Preferire ai grassi saturi (burro, derivati animali), i grassi monoinsaturi (olio d'oliva) o polinsaturi (olio di semi). Ottima la frutta e verdura ma attenzione a non assumere troppi liquidi. Cucinate con poco sale e non aggiungetene dopo la cottura, evitate di abusare dei cibi conservati (insaccati, scatollette, ecc). Pesatevi ogni giorno. Una variazione di peso oltre 1 kg in 2-3 giorni che state trattenendo (se aumentate) o perdendo (se calate) troppi liquidi. Sarà quindi necessario o ridurre la quantità di liquidi introdotti (acqua, bevande varie, frutta, minestre, verdura) o variare la dose del diuretico (ad esempio LASIX-

[Back to Workspaces](#)
[Back to Task](#) | [Open document list](#)

Alphab... ▾ 14pt ▾ 1 ▾

Assets ▾



Coreference

[View Details](#)
[Attribute View](#)

Completed ▾

TC1.docx

- 1 TC Cospicuo e diffuso versamento ematico subaracnoideo prevalentemente sovratentoriale.
- 2 Perdita differenziazione bianca/grigia in sede temporale bilaterale.
- 3 Sottile raccolta ematica extraassiale temporo-frontale sinistra e temporo polare destra.
- 4 Piccola bolla aerea temporo polare sinistra.
- 5 Poco riconoscibili le cisterne attorno al tronco.

Entity Mention

Type Subtype Role

- Anatomia

- Collocazione

- Diagnosi

- Negazione

- Osservazione

- Quantita

- Sintomo

Rule-based Model ▾

Machine Learning Model ▾

Pre-annotation

IBM Watson Knowledge Studio

rja@it

[Back to Workspaces](#)
[Back to Task](#) | [Open document list](#)

Alphab... ▾ 14pt ▾

Assets ▾

Documents

Entity Types

Relation Types

Dictionaries

Rule-based Model ▾

Machine Learning Model ▾

Pre-annotation

Annotations

Performance

Versions



Settings

Help



Coreference

TC1.docx




Relation Type

- CollocAnat
- CollocDiag
- CollocOsserv
- CollocSint
- DiagAnatomia
- NegDiag
- NegOsservaz
- NegSint
- OsservazAnatomia
- QuantDiag
- QuantOsserv
- QuantSint

5) Are only english terms found in the FMA?


The FMA contains 8,500 Latin, 4,700 French, 500 Spanish, 350 German terms.

AI for dynamic healthcare and medical knowledge



The system is continuously updated in a dynamic fashion, to untap newest findings

Thank you for your attention



Email: bob@ralexander.it

Twitter: @rjalex

Linkedin: <https://www.linkedin.com/in/rjalexander>

